Clinical trials: PCSK9
Acute Ischemic Stroke
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
This is a prospective, multicenter, randomized controlled clinical study to evaluate the efficacy of PCSK9 inhibitor in addition to standard therapy in patients with acute ischemic stroke undergoing endovascular therapy.
- Trial name
- PCSK9-PROVE (NCT07174375)
- Testing
- PCSK9 inhibitor
- Where
- 12 sites in China
- Volunteers
- 478 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hypercholesterolemia and Mixed Dyslipidemia
A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody, in combination with a stable…
- Trial name
- NCT07278830
- Testing
- SAL003 140mg+Atorvastatin, SAL003 420mg+Atorvastatin
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hyperlipidemia
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneously once every 2 weeks (Q2W) and once monthly (QM), compared with placebo, on percent change from baseline in low-density lipoprotein…
- Trial name
- RUTHERFORD-2 (NCT01763918)
- Testing
- Evolocumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 331 people
- Sponsor
- Amgen
Lipoprotein Metabolism, PCSK9
Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults
Background: Metabolism is what the body does to turn food into energy. Omega-3 fatty acids are substances found in foods such as cold-water fish and shellfish that are essential for good health.
- Conditions
- Lipoprotein Metabolism, PCSK9, Proteomics
- Trial name
- NCT02514070
- Testing
- EPA-rich fish oil, DHA-rich fish oil
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases
Immunomodulatory Effects of PCSK9 Inhibition
Cardiovascular disease (CVD) represents the leading cause of death worldwide. While medications, such as statins, significantly reduce atherosclerotic CVD (ASCVD) risk by lowering low density lipoprotein levels, they may also…
- Conditions
- Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation
- Trial name
- INSPIRAR (NCT05720156)
- Testing
- 99mTc-tilmanocept SPECT/CT scanning
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alcohol Associated Liver Disease, Heavy Drinking Behavior
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Background: Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver…
- Trial name
- NCT04781322
- Testing
- Alirocumab
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Myocardial Ischaemic Syndrome, Coronary Heart Disease
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)
This is a multi-center, randomized controlled study to investigate whether early offering PCSK9 inhibitor can protect against negative inflammatory response and organ dysfunction after coronary artery bypass grafting (CABG).
- Trial name
- PANDA (NCT06730802)
- Testing
- PCSK9 inhibitor, Statin
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Nanjing Medical University
Hypertension, Dyslipidemias
Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels
This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach.
- Conditions
- Hypertension, Dyslipidemias, Inflammatory Response, Chronic Inflammation
- Trial name
- MRDLT (NCT06622304)
- Where
- China
- Volunteers
- 250,736 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Aortic Valve Stenosis
PCSK9 Inhibitors in the Progression of Aortic Stenosis
Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis, through a randomized controlled trial.
- Trial name
- NCT03051360
- Testing
- PCSK9 Inhibitor [EPC]
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Seoul National University Hospital
Efficacy and Safety, Heterozygous Familial Hypercholesterolemia
Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia
This study plans to enroll several patients with heterozygous familial hypercholesterolemia, randomly assigned to different dose groups, and randomly receiving subcutaneous injection of IBI306150 mg or placebo every two weeks: or…
- Conditions
- Efficacy and Safety, Heterozygous Familial Hypercholesterolemia, PCSK9
- Trial name
- NCT04759534
- Testing
- protein convertase subtilisin/kexin type 9 inhibitor
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Shenzhen People's Hospital
Atherosclerotic Cardiovascular Disease
A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol: CTSU_MDCO-PCS-17-01 (CKJX839B12301)).
- Trial name
- ORION-4 (NCT03705234)
- Testing
- Inclisiran
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 16,124 people
- Sponsor
- University of Oxford
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI
Investigators aimed to evaluate efficacy and safety of early Initiation of evolocumab and combination lipid-lowering agent (statin + Ezetimibe) on lipid profiles changes in patients with ACS undergoing PCI
- Trial name
- C-STAR (NCT05661552)
- Testing
- Evolocumab 140 MG/ML, Rosuvastatin 5mg, Ezetimibe 10mg
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Yonsei University